Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Plus Pemetrexed Maintenance in Advanced Non-squamous NSCLC
NCT03190239Phase 2Withdrawn
- Sponsor
- Xinqiao Hospital
- Start
- Jul 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Xinqiao Hospital. Planned start Jul 2017; status: withdrawn.
02
Drugs
Rivoceranib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03190239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03190239.